<DOC>
	<DOCNO>NCT01238575</DOCNO>
	<brief_summary>The purpose study determine whether guanfacine ( trade name Intuniv ) combination methylphenidate ( also know Ritalin ) helpful treat hyperactivity child adolescent Pervasive Developmental Disorders ( PDDs ) .</brief_summary>
	<brief_title>Guanfacine Treatment Hyperactivity Pervasive Developmental Disorder</brief_title>
	<detailed_description>Pervasive Developmental Disorders ( PDDs ) group condition include Autistic Disorder , Asperger 's disorder call Pervasive Developmental Disorder - Not Otherwise Specified . Children PDD show delay speech language reduce social interaction . Some child PDD also problem overactivity , impulsiveness distractability . These behavior see child Attention Deficit Hyperactivity Disorder ( ADHD ) . Extended release guanfacine ( Intuniv ) FDA-approved treatment child ADHD . The purpose study evaluate whether Intuniv effective treatment ADHD symptoms child PDD . This study four part : 8-week double-blind trial , 8-week blind extension phase ( positive responder ) , 8-week open-label trial , 4-week add-on study . Following confirmation eligibility , participant randomly assign receive either guanfacine placebo 8-week double-blind trial . Children show improvement 8 week treatment continue assign treatment additional 8 week ( blind extension phase ) . Children show partial improvement guanfacine offer 4 week treatment guanfacine plus methylphenidate ( add-on study ) . Children show improvement placebo offer 8 week treatment guanfacine ( open-label trial ) . Children show improvement guanfacine exit study . Side effect treatment response assess regularly schedule visit . The study protocol formally revise Yale University IRB May 2013 address early close enrollment due reduction funding . The original anticipated enrollment number 112 subject reduce 60 subject . The study statistician consult prior enrollment closure address issue relate statistical power adjustment make final statiscal analysis plan .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Developmental Disabilities</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>Diagnosis PDD ( PDDNOS , Asperger 's Disorder , Autistic Disorder ) Hyperactivity Between age 5 year 0 month 13 year 11 month . Weight &gt; /= 15 kg ( 33 lb ) A mental age least 18 month Prior fail treatment adequate trial guanfacine last 2 year Concurrent treatment another psychoactive medication</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Pervasive Developmental Disorders</keyword>
	<keyword>PDD</keyword>
	<keyword>PDD-NOS</keyword>
	<keyword>Autistic Disorder</keyword>
	<keyword>Autism</keyword>
	<keyword>Asperger 's Disorder</keyword>
	<keyword>Hyperactivity</keyword>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>ADHD</keyword>
	<keyword>Medication</keyword>
	<keyword>Drug</keyword>
	<keyword>Guanfacine</keyword>
	<keyword>Intuniv</keyword>
	<keyword>Placebo</keyword>
	<keyword>Methylphenidate</keyword>
</DOC>